HILDEN and ROSTOCK, Germany and GERMANTOWN, Maryland,
QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and CENTOGENE AG today announced a collaboration and co-marketing agreement to provide customers more complete Sample to Insight research and clinical testing solutions in rare genetic diseases. CENTOGENE is a leading rare disease company providing insights into the complex interaction between genetics, biochemistry and clinical phenotypes of patients with hereditary disorders. More than 4,000 known genetic disorders are estimated to affect roughly 1 in 10 individuals.
Click here for the full press release https://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-09-Centogene?sc_lang=en
Contacts: QIAGEN Public Relations Dr. Thomas Theuringer e-mail: [email protected] +49-2103-29-11826
Investor Relations John Gilardi e-mail: [email protected] +49-2103-29-11711
CENTOGENE CEO´s office Doreen Niemann e-mail: [email protected] +49-381-203-652-181
SOURCE Qiagen N.V.
Subscribe to our Free Newsletters!
Parkinson's disease (PD) is a chronic and progressive disease of the nervous system, causing ...
Iridectomy is a procedure in which an opening is made in the iris of the eye.
Hand hygiene is a simple and affordable technique to prevent infections.View All